These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 9764577)

  • 1. Tau expression in model adenocarcinomas correlates with docetaxel sensitivity in tumour-bearing mice.
    Veitia R; Bissery MC; Martinez C; Fellous A
    Br J Cancer; 1998 Oct; 78(7):871-7. PubMed ID: 9764577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteolysis of microtubule associated protein 2 and sensitivity of pancreatic tumours to docetaxel.
    Veitia R; David S; Barbier P; Vantard M; Gounon P; Bissery MC; Fellous A
    Br J Cancer; 2000 Aug; 83(4):544-9. PubMed ID: 10945505
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Class III beta-tubulin, a marker of resistance to paclitaxel, is overexpressed in pancreatic ductal adenocarcinoma and intraepithelial neoplasia.
    Lee KM; Cao D; Itami A; Pour PM; Hruban RH; Maitra A; Ouellette MM
    Histopathology; 2007 Oct; 51(4):539-46. PubMed ID: 17714470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical pharmacology of docetaxel.
    Bissery MC
    Eur J Cancer; 1995; 31A Suppl 4():S1-6. PubMed ID: 7577097
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preclinical profile of docetaxel (taxotere): efficacy as a single agent and in combination.
    Bissery MC; Vrignaud P; Lavelle F
    Semin Oncol; 1995 Dec; 22(6 Suppl 13):3-16. PubMed ID: 8604451
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of microtubule-associated proteins on the differential effects of paclitaxel and docetaxel.
    Fromes Y; Gounon P; Veitia R; Bissery MC; Fellous A
    J Protein Chem; 1996 May; 15(4):377-88. PubMed ID: 8819014
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Paclitaxel-resistant cells have a mutation in the paclitaxel-binding region of beta-tubulin (Asp26Glu) and less stable microtubules.
    Hari M; Loganzo F; Annable T; Tan X; Musto S; Morilla DB; Nettles JH; Snyder JP; Greenberger LM
    Mol Cancer Ther; 2006 Feb; 5(2):270-8. PubMed ID: 16505100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Docetaxel: a review of its pharmacology and clinical activity.
    Trudeau ME
    Can J Oncol; 1996 Jun; 6(1):443-57. PubMed ID: 8853517
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanisms of taxotere-related drug resistance in pancreatic carcinoma.
    Liu B; Staren ED; Iwamura T; Appert HE; Howard JM
    J Surg Res; 2001 Aug; 99(2):179-86. PubMed ID: 11469885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer.
    Chang JC; Wooten EC; Tsimelzon A; Hilsenbeck SG; Gutierrez MC; Elledge R; Mohsin S; Osborne CK; Chamness GC; Allred DC; O'Connell P
    Lancet; 2003 Aug; 362(9381):362-9. PubMed ID: 12907009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Docetaxel in anthracycline-resistant metastatic breast cancer.
    Hui YF; Ignoffo RJ
    Cancer Pract; 1997; 5(2):124-7. PubMed ID: 9110651
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of patients resistant to paclitaxel therapy.
    Valero V
    Anticancer Drugs; 1996 Aug; 7 Suppl 2():17-9. PubMed ID: 8862705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The scientific rationale for developing taxoids.
    Aapro M
    Anticancer Drugs; 1996 Aug; 7 Suppl 2():33-6. PubMed ID: 8862709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Docetaxel enhances tumor radioresponse in vivo.
    Mason KA; Hunter NR; Milas M; Abbruzzese JL; Milas L
    Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2431-8. PubMed ID: 9815644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity of docetaxel in paclitaxel-resistant ovarian cancer cells.
    Sato S; Kigawa J; Kanamori Y; Itamochi H; Oishi T; Shimada M; Iba T; Naniwa J; Uegaki K; Terakawa N
    Cancer Chemother Pharmacol; 2004 Mar; 53(3):247-52. PubMed ID: 14610615
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Microtubule-associated parameters as predictive markers of docetaxel activity in advanced breast cancer patients: results of a pilot study.
    Bernard-Marty C; Treilleux I; Dumontet C; Cardoso F; Fellous A; Gancberg D; Bissery MC; Paesmans M; Larsimont D; Piccart MJ; Di Leo A
    Clin Breast Cancer; 2002 Dec; 3(5):341-5. PubMed ID: 12533264
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Docetaxel.
    Leahy M; Howell A
    Br J Hosp Med; 1997 Feb 19-Mar 4; 57(4):141-4. PubMed ID: 9166374
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Docetaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of metastatic breast cancer.
    Fulton B; Spencer CM
    Drugs; 1996 Jun; 51(6):1075-92. PubMed ID: 8736622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The relationships between the chemosensitivity of human gastric cancer to paclitaxel and the expressions of class III β-tubulin, MAPT, and survivin.
    He W; Zhang D; Jiang J; Liu P; Wu C
    Med Oncol; 2014 May; 31(5):950. PubMed ID: 24722794
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of paclitaxel and docetaxel activity on human ovarian carcinoma xenografts.
    Nicoletti MI; Lucchini V; D'Incalci M; Giavazzi R
    Eur J Cancer; 1994; 30A(5):691-6. PubMed ID: 7915909
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.